A blockbuster breast cancer niche has Roche and Sanofi in the lead

A blockbuster breast cancer niche has Roche and Sanofi in the lead

From Novartis, Bristol MS meds to new ADCs, here are 2020’s blockbuster drug launches

From Novartis, Bristol MS meds to new ADCs, here are 2020's blockbuster drug launches

Liver Cancer Insight Report: Current Therapies, Drug Pipeline and Outlook

Liver Cancer Insight Report: Current Therapies, Drug Pipeline and Outlook

Special Reports The 10 most-anticipated drug launches of 2020

Special Reports The 10 most-anticipated drug launches of 2020

Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis

Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!! Earlier this week, Active Biotech, based in Lund, Sweden, announced that it was abandoning its neurology focus, including MS. The overall focus is on the company’s wholly-owned lead assets, laquinimod and tasquinimod. Laquinimod is an oral small molecule developed primarily for … Συνεχίστε να διαβάζετε Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis.

Myeloma cell therapies, now in pharma hands, move into spotlight

Myeloma cell therapies, now in pharma hands, move into spotlight